Umoja Biopharma Announces Oversubscribed $100 Million Series C Financing to Advance In Vivo CAR T Pipeline through Key Oncology Clinical Milestones
14 janv. 2025 07h00 HE
|
Umoja Biopharma, Inc.
Series C financing co-led by Double Point Ventures and DCVC Bio Proceeds to support the clinical development of VivoVec™ derived in vivo CAR T cells SEATTLE, Jan. 14, 2025 (GLOBE NEWSWIRE) --...
Umoja Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
06 janv. 2025 16h30 HE
|
Umoja Biopharma, Inc.
SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, today...
Umoja Biopharma to Present at the 7th Annual Evercore ISI HealthCONx Conference
26 nov. 2024 09h05 HE
|
Umoja Biopharma, Inc.
SEATTLE, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo and off-the-shelf cell therapies that aim to realize the full reach and promise of...
Umoja Biopharma Appoints Scott Myers as Chairman of its Board of Directors
21 nov. 2024 08h05 HE
|
Umoja Biopharma, Inc.
SEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo and off-the-shelf therapies that aim to realize the full reach and promise of CAR...
Umoja Biopharma Announces Oral and Poster Presentations at the 66th American Society of Hematology Annual Meeting
05 nov. 2024 09h05 HE
|
Umoja Biopharma, Inc.
SEATTLE, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
Umoja Biopharma Announces Poster Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer
04 oct. 2024 09h05 HE
|
Umoja Biopharma, Inc.
SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
Umoja Biopharma Announces Oral Presentation at the American College of Rheumatology Convergence 2024
30 sept. 2024 16h30 HE
|
Umoja Biopharma, Inc.
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
Umoja Biopharma to Present at the 9th Annual CAR-TCR Summit
11 sept. 2024 16h30 HE
|
Umoja Biopharma, Inc.
SEATTLE, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV111, a CD19 Directed in situ CAR T for Hematologic Malignancies
31 juil. 2024 07h00 HE
|
Umoja Biopharma, Inc.
- UB-VV111 is potentially the first in situ generated CD19 chimeric antigen receptor (CAR)-T cell therapy to be evaluated in humans in the hematology setting - - First patient expected to be dosed by...
Umoja Biopharma Announces Publication in Blood Highlighting Successful Generation of In Vivo CAR T-cells in Non-Human Primate Modeling
13 juin 2024 08h00 HE
|
Umoja Biopharma, Inc.
Umoja Biopharma Announces Publication in Blood Highlighting Successful Generation of In Vivo CAR T-cells in Non-Human Primate Modeling